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The lack of effective pharmacological treatments for acute kidney injury (AKI) remains a significant 
public health problem. Given the involvement of apoptosis and regulated necrosis in the initiation 
and progression of AKI, the inhibition of cell death may contribute to AKI prevention/recovery. 
Curcuminoids are a family of plant polyphenols that exhibit attractive biological properties that make 
them potentially suitable for AKI treatment. Now, in cultured tubular cells, we demonstrated that a 
crosslinked self-assembled star-shaped polyglutamate (PGA) conjugate of bisdemethoxycurcumin (St-
PGA-CL-BDMC) inhibits apoptosis and necroptosis induced by Tweak/TNFα/IFNγ alone or concomitant 
to caspase inhibition. St-PGA-CL-BDMC also reduced NF-κB activation and subsequent gene 
transcription. In vivo, St-PGA-CL-BDMC prevented renal cell loss and preserved renal function in mice 
with folic acid-induced AKI. Mechanistically, St-PGA-CL-BDMC inhibited AKI-induced apoptosis and 
expression of ferroptosis markers and also decreased the kidney expression of genes involved in tubular 
damage and inflammation, while preserving the kidney expression of the protective factor, Klotho. 
Thus, due to renal accumulation and attractive pharmacological properties, the application of PGA-
based therapeutics may improve nephroprotective properties of current AKI treatments.
Acute kidney injury (AKI) involves a sudden and generally transient loss of glomerular filtration leading to the 
retention of damaging nitrogenous byproducts normally excreted in the urine. Independently of its etiology, 
AKI usually implies extensive renal parenchymal injury, which, in the case of unsuccessful repair, favors the 
progression of AKI to chronic kidney disease (CKD). The mortality of AKI may be as high as 50%, and currently, 
there exist no specific therapies to attenuate AKI or accelerate recovery beyond dialysis1. Thus, there is an unmet 
clinical need for novel AKI treatments.
During the initial stages of AKI, proximal renal tubular cell death triggers a cascade of damaging events, 
including inflammation, that amplifies kidney injury2,3. Thus, the control and execution of apoptosis and several 
kinds of regulated necrosis depend on environmental conditions as well as on the recruitment of intracellular cell 
death pathways. Distinct forms of cell death are amenable to pharmacological modulation. Strategies to specif-
ically inhibit caspases, the final executioners of apoptosis, decrease apoptosis, inflammation, and improve renal 
function in experimental ischemia/reperfusion or septic AKI4,5. However, the inhibition of overall caspase activity 
failed to improve nephrotoxic AKI6. In this regard, caspase activation is involved in cellular events beyond cell 
death regulation, including, among others, cell cycle and the regulation of proliferation7,8. Strategies that interfere 
with initial or intermediate regulators of caspase activity, like protein kinases, survival factors, cytokine death 
receptors, oxidative stress factors, apoptosome factors, and tumor-suppressor, cell cycle and heat shock proteins, 
have been shown to decrease the severity of AKI2. Additionally, molecules involved in the regulation of necrosis, 
including necroptosis, pyroptosis, and ferroptosis, are also involved in AKI initiation and progression6,9,10.
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Curcuminoids are a family of natural compounds derived from the herb Curcuma longa; the extracted mix-
ture (turmeric powder) mostly comprises curcumin and copurified demethoxycurcumin and bisdemethoxycur-
cumin (BDMC). Curcuminoids have multiple potentially beneficial actions, such as preventing parenchymal 
cell death, inflammation, abnormal cell proliferation, and fibrosis through NF-κB inhibition and antioxidative 
effects11. Indeed, curcumin protects from murine AKI induced by ischemia/reperfusion, glycerol-induced rhab-
domyolysis, and cisplatin nephrotoxicity12,13. BDMC also prevents kidney fibrosis by activating fibroblast apop-
tosis14. Despite their efficacy and safety profile, the extremely low bioavailability of curcuminoids, resulting from 
a combination of poor solubility and low stability, limits their therapeutic application15. Moreover, maintaining 
the beneficial pharmacological properties of curcuminoids when introducing chemical modifications in their 
molecular architecture to improve bioavailability remains a critical challenge.
Nanotechnology-based drug carriers, including polymeric micelles, liposomes, polymeric nanoparticles, 
nanoemulsions, nanosuspensions, and polymer conjugates can enhance the availability and effective therapeutic 
outcomes of curcuminoids16,17. Specifically, polymer therapeutics are “new chemical entities” (nanomedicines 
with demonstrated clinical benefits) that can overcome the low bioavailability of free drugs through an increased 
capacity to i) cross biological barriers, ii) reach specific intracellular compartments and iii) optimize pharmacoki-
netics18,19. Importantly, carboxylated polymers exhibit renal targeting properties and therefore represent a means 
to target nephroprotectants to the kidney20,21. In particular poly-L-glutamic acid (PGA) possesses additional 
advantages such as excellent water solubility, biocompatibility, non-immunogenicity, biodegradability, and mul-
tivalency (allowing dual targeting or drug combination therapy)22.
PGA homopolymers, star-shaped PGAs, and crosslinked-star-shaped PGAs purified through covalent capture 
of self-assembled nanostructures modulate cellular uptake and PK23,24. Also, these carriers present a high control 
on the polymerization process as well as the possibility of post-polymerization with drugs as well as targeting 
residues25, increasing, if needed, the potential of directed molecule design to improve their renal targeting capac-
ity. Herein, we have now assessed the nephroprotective potential of a crosslinked self-assembled star-shaped 
polyglutamate-BDMC (St-PGA-CL-BDMC) conjugate23,24 in experimental cellular and animal models of AKI. 
We discovered the superior nature of St-PGA-CL-BDMC when compared to the “free” form of BDMC with 
regards to protection in cultured cells treated with lethal proinflammatory stimuli and experimental murine 
nephrotoxic AKI models.
Materials and Methods
St-PGA-CL-BDMC synthesis. The crosslinlinked star-shaped polyglutamate (St-PGA-CL) polymer was 
synthesized according to a previously published protocol23. The molecular weight of poly (gamma benzyl-L-gluta-
mates) was 31.5 kDa, and the polydispersity index (PDI) 1.26. The polymer was benzyl deprotected using trifluo-
roacetic acid (TFA)/Hydrogen bromide (HBr) as previously described and then modified with propargylamine 
(13% mol glutamic acid units GAU) and oligoethylene glycol azide (7% mol GAU units) by post-polymerization 
modification as described previously25,26. The self-assembly and crosslinking of the polymer were performed fol-
lowing recently reported procedures24 (See Tables S1–3 for further details on carrier characterization).
Conjugation of BDMC was carried out using the acid form of the St-PGA-CL and proceeded as follows. 
Briefly, in a two-necked round bottom flask, fitted with a stirrer bar and two septae, the star polymer was dis-
solved in 10 mL of anhydrous dimethylformamide (DMF) under nitrogen atmosphere. After that, 0.3 eq. of the 
GAU of DIC (diisopropylcarbodiimide) was added in 5 mL of anhydrous DMF. The reaction was left to proceed 
for 20 minutes. Then, 0.2 eq. of the GAU of BDMC was added to the reaction mixture, followed by a catalytic 
amount of DMAP. The pH was maintained around 7. The reaction was then left to proceed for 72 hours. For puri-
fication, the mixture was poured into a large excess of diethyl ether. The polymer conjugate was purified using 
LH-20 column in DMF. After isolation, the yellowish solid was converted into sodium salt form by the careful 
addition of NaHCO3 (1 M). Then, the aqueous solution was washed with diethyl ether till no yellowish colora-
tion was found in the organic phase. Finally, the aqueous phase product was purified by dialysis using Vivaspin® 
MWCO 5000 and then freeze-dried. BDMC content was determined by UV-VIS at 405 nm using a calibration 
curve with free BDMC. Yield: 90% BDMC content 8.9% mol GAU, 14.9% wt (See Materials and Methods for 
further details on St-PGA-CL-BDMC characterization).
Animal models. All the procedures on animals were performed according to the European Community 
and Animal Research Ethical Committee guidelines. The animal protocols were approved by the Instituto de 
Investigación Sanitaria Fundación Jiménez Díaz Animal Research Ethical Committee (body authorized by the 
Dirección General de Medioambiente, Consejería de medioambiente y Ordenación del Territorio, Comunidad de 
Madrid, RD 53/2013). AKI was induced in female C57BL/6 wild type mice (10–12 weeks old) employing a single 
i.p. dose of 250 mg/kg folic acid (FA). Experimental FA-AKI recapitulates the sequence of pathological as well as 
adaptive responses during human AKI, including several cell death programs involved in apoptosis and regulated 
necrosis6,9,27. Some mice also received a retro-orbital injection of St-PGA-CL-BDMC (4 mg drug equivalent/kg) 
under anesthesia, 4 h before FA administration. Control mice received the FA vehicle (0.3 M sodium bicarbonate, 
i.p.). Mice were euthanized under anesthesia (ketamine/xylazine) 48 h after FA administration, corresponding to 
the acute stage of AKI, characterized by intense cell death accompanied by inflammation and renal dysfunction. 
Creatinine and urea plasma levels were measured at the institutional Central Laboratory. Kidneys were perfused 
in situ with cold saline before removal. One kidney was snap frozen in liquid nitrogen for RNA and protein stud-
ies and the other fixed and paraffin-embedded for immunohistochemistry.
Cell culture. MCT cells, a cultured line of mouse proximal tubular epithelial cells28, were grown in RPMI 
1640 (GIBCO, Grand Island, NY) supplemented with 10% decomplemented fetal bovine serum (DFBS), 2 mM 
glutamine, 100 U/mL penicillin and 10 mg/mL streptomycin, in 5% CO2 at 37 °C. For experiments, cells were 
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first arrested using serum-free medium, and subconfluent cells stimulated with a mixture of cytokines contain-
ing 100 ng/ml human TWEAK (Merck-Millipore), 30 ng/ml TNFα, 30 U/ml interferon-γ (INFγ, PeproTech). In 
some experiments, cells were pre-treated with free curcumin (1 mM stock solution in DMSO) (Sigma-Aldrich, 
Merck), free BDMC (10 mM stock solution in DMSO) (TCI Europe), or St-PGA-CL-BDMC. St-PGA-CL-BDMC 
dosing was based on the BDMC batch loaded into the conjugate to calculate the drug equivalents in the assay 
fraction.
Cell death assays. For assessment of the overall death rate, cells were washed with PBS following stimula-
tion and then incubated with 0.5 mg/ml MTT (Sigma, Merck) for 1 h at 37 °C to detect changes in the metabolic 
activity. After this step, the MTT solution was withdrawn, and cells allowed to air dry. Finally, deposits of reduced 
MTT were dissolved with DMSO, and their absorbance read at 570 nm. To assess the degree of plasma mem-
brane damage, cells were seeded in 96 well plates (6000 cells/well). Following incubation, citotoxicity/cytolysis 
was based on measurements of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells 
into the culture supernatant after reduction of tetrazolium salt (pale yellow) to formazan salt (red) and colori-
metric detection (Cytotoxicity Detection KitPLUS (LDH), Roche). For assessment of apoptosis by flow cytometry, 
remnant adhered cells after treatment were pooled with spontaneously detached cells, centrifuged, and washed 
with PBS and then incubated in 100 mg/ml propidium iodide, 0.05% Nonidet P-40, and 10 mg/ml RNase A in 
phosphate-buffered saline (PBS) at 4 °C for more than 1 h. After this step, cells were centrifuged, and the cellular 
pellet suspended in PBS. The number of apoptotic cells with decreased DNA staining (G0 hypodiploid cells) 
was counted by flow cytometry using BD CellQuest Software (BD Biosciences) and the percentage of apoptosis 
calculated in relation to the total number of cells. In vivo cell death was assessed by TUNEL assay performed 
in 3 µm-thick sections of paraffin-embedded renal tissue (ApopTag®Peroxidase in Situ apoptosis detection kit, 
Millipore, Merck) according to the manufacturer’s instructions.
Western blotting. Total protein extracts were prepared by homogenizing samples in lysis buffer (50 mmol/L 
Tris, 150 mmol/L NaCl, 2 mmol/L EDTA, 2 mmol/L EGTA, 0.2% Triton X-100, 0.3% NP-40, 0.1 mmol/L 
PMSF, 25 mmol/L NaF). For nuclear extracts, the NE-PERTM nuclear and cytoplasmic extraction kit (Pierce, 
Thermofisher Scientific) was used according to the manufacturer’s instructions. Proteins were separated by 
SDS-PAGE under reducing conditions and then blotted onto nitrocellulose membranes. Membranes were 
blocked with 5% defatted milk in TBS-T (0.05 mol/L Tris, 0.15 mol/L NaCl, 0.05% Tween 20, pH 7.8). Thereafter, 
membranes were probed overnight at 4 °C with primary antibodies in the same blocking solution or 5% BSA in 
TBS-T and then incubated with secondary HRP-conjugated antibodies for 1 h at room temperature. Primary 
antibodies were: phospho-MLKL (1/500; ab196436; Abcam, Inc.); cleaved caspase-8 (1/1000, 8592, Cell Signaling 
Technology); p-cJUN (1/1000, 3270, Cell Signaling); cleaved IL-33 (1/1000; AF3626; R&D Systems), heme 
oxygenase-1 (HO-1, 1/2000, ADI-OSA-150-D, Enzo) and p65 (1/1000, 8242, Cell Signaling Technology). Total 
protein content for loading controls was assessed with Ponceau Red or by means of the fluorescence incorporated 
into tryptophan amino acids of proteins samples ran in Stain-FreeTM gels (BioRad).
Immunofluorescence. Cells were fixed in 4% paraformaldehyde/PBS, permeabilized in 0.1% Triton X-100/
PBS, washed in 1% BSA/PBS, blocked with 4% BSA/PBS, and stained with rabbit polyclonal anti-p65 (1:200, 
sc-8008, Santa Cruz Biotechnology). Cells were incubated with Alexa secondary antibodies (Invitrogen) and 
nuclei counterstained with propidium iodide or 4′,6-diamidino-2-phenylindole (DAPI). Cells were analyzed 
using a Confocal System TCS SP5 (Leica).
Cell uptake of St-PGA-CL-BDMC was assessed by live fluorescence imaging in microscopy chambers 
(1 µ-slides) of cultured cells treated with 10 µM St-PGA-CL-BDMC for 6 h. After stimulation, cells were washed 
with PBS-BSA 0.1% and then incubated for 20 min with the lysosomal marker LysoTrackerTMGreen DND-26 
(Invitrogen). After washing with PBS-BSA 0.1%, cells were left in culture medium and placed in the microscope 
culture chamber (37 °C, 5% CO2) and analyzed using the same confocal system.
Gene expression. Total RNA was extracted using Tripure (Roche), and 1 μg was reverse transcribed with 
the High-Capacity cDNA Archive Kit (Applied Biosystems, Thermofisher Scientific). Quantitative PCR was per-
formed in a 7500 Real-Time PCR System with Prism 7000 System SDS Software (Applied Biosystems). RNA 
expression was corrected for endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. 
Fluorogenic (FAM or VIC) predesigned primers were from Applied Biosystems.
Biochemical and histological studies. Creatinine and Urea plasma levels were assessed by biochemical 
methods intended for automatic measurements in a biochemistry analyzer (Roche/Hitachi cobas® c701/702) 
based on the enzymatic decomposition with creatininasa and ureasa, respectively, then followed by colorimetric 
detection of the reactions products.
Tubular injury was assessed in kidney tissue sections stained with hematoxylin–eosin by a renal pathologist 
(P.C) blinded as to the nature of the samples. Evidence of tubulointerstitial injury including pyknosis/apoptosis, 
activity, proliferation/regeneration, flattening, necrosis, calcifications and intratubular precipitations were indi-
vidually scored on a semiquantitative scale from 0 to 3. Results from each item were added to yield the overall 
tubular injury score (maximal value 21) as previously described29.
For immunohistochemistry, endogenous peroxidase was blocked and then sections were incubated overnight 
at 4 °C with the following primary antibodies: PCNA (1:50; sc-7907, Santa Cruz); active caspase-3 (1/100, G748A, 
Promega); phospho-cJUN (1/250, 3270, Cell Signaling) or 4-hydroxynonenal (4-HNE) (1:400; ab46545; Abcam). 
Finally, sections were washed, stained with 3,3′-diaminobenzidine (DAB) as chromogen (Dako, Denmark), coun-
terstained with Carazzi’s hematoxylin, dehydrated and mounted in DPX medium (Merck, NJ, USA).
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Statistical analysis. Statistical analysis was performed using SPSS 11.0 (SPSS), expressing the results as 
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Figure 1. St-PGA-CL-BDMC synthesis and main physicochemical characteristics. (A) Schematic 
representation of the synthesis of St-PGA-CL-BDMC (4) by means of bisdemethoxycurcumin (BDMC) 
conjugation to St-PGA-CL (3) after azide (1) and alkyne (2) bearing St-PGAs co-assembly and covalent capture 
by copper catalyzed alkyne-azide cycloaddition. (B) Confocal immunofluoresce in murine tubular cells (MCT) 
treated with 10 µM St-PGA-CL-BDMC (green fluorescence) for 1 to 6 h to analyze the intracellular uptake and 
transit of the conjugate. Nuclei were counterstained with DAPI (blue fluorescence). White arrows indicate the 
captured conjugate at early time points (1–3 h) and yellow arrowheads point to the conjugate inside lysosomes 
at a later time points (6 h). Control cells that were left untreated displayed a faint autofluorescence. Original 
magnification x200. Scale bar 25 µM.
Compound wt% BDMCa Size (Rh, nm)b Z-pot (mV)c
St-PGA-CL-BDMC 14.9% 40.2 ± 2.4 −38.6 ± 2.2
Table 1. St-PGA-CL-BDMC characterization including drug loading, size and zeta potential. aDetermined by 
UV-VIS at 405 nm. bDetermined by dynamic light scattering techniques using a conjugate solution of 1 mg/mL 
in ddH2O. Size expressed in number mean. cDetermined using Zetasizer using a conjugate solution of 1 mg/mL 
in 1 mM solution of KCl.
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Figure 2. St-PGA-CL-BDMC inhibits apoptosis and necroptosis in cultured renal tubular cells. (A) Percentage 
of cell viability according to the metabolic activity assessed by the MTT assay in cultured murine MCT tubular 
cells stimulated for 24 h with 100 ng/ml Tweak/30 ng/ml TNFα/30 U/ml INFγ (TTI) alone or following 
pretreatment with variable doses of 10 µM St-PGA-CL-BDMC for 1 h before stimulation. #p < 0.001 vs control; 
§p < 0.05 and *p < 0.001 vs TTI (n = 5–10 independent experiments). (B) Percentage of haplodiploid apoptotic 
cells corresponding to the cell population distributed along the sub-G1 region of the cell cycle identified by 
flow cytometry of cell DNA content. Cells were subjected to TTI alone under the same conditions as in A or 
pretreated with the indicated doses of 10 µM St-PGA-CL-BDMC. (C) Percentage of LDH activity assessed in cell 
culture supernatants treated as in A. In every individual experiment, the activity of supernanant LDH in cells 
incubated with St-PGA-CL-BDMC and TTI was expressed as a percentage of the activity in TTI-exposed cells 
considered to be 100%. *p < 0.01 vs TTI (n = 5). (D) Percentage of cell viability inferred from the metabolic 
activity assessed by the MTT assay in tubular cells stimulated for 8 h with 20 µM zVAD-fmk plus TTI (z/
TTI) alone or following pretreatment with 10 µM St-PGA-CL-BDMC for 1 h before stimulation. #p < 0.05 vs 
control; *p < 0.05 vs TTI (n = 4). (E) Representative contrast phase microphotographs of tubular cells left 
untreated (Control) or stimulated with z/TTI alone or in the presence of 10 µM St-PGA-CL-BDMC (original 
magnification 200x, scale bar 200 µm). The figure shows that St-PGA-CL-BDMC markedly decreased z/TTI-
induced morphological changes and detachment. Results are presented as mean ± SD. (F) Phosphorylated 
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Results
Rational design of renal targeted curcuminoid conjugates and interaction with tubular cells. 
We synthesized a novel family of biodegradable St-PGA-CL-BDMC conjugates to enhance solubility and promote 
renal targeting of BDMC while also improving BDMC pharmacokinetics. We conjugated BDMC to St-PGA-CL 
polymeric carrier employing post-polymerization modification approaches25, due to the reported renal accumu-
lation after intravenous administration23,24. We carried out the conjugation of BDMC by the carbodiimide-medi-
ated activation of St-PGA-CL catalyzed by DMAP. After purification, we detected a St-PGA-CL-BDMC conjugate 
(90% yield) with a total BDMC loading of 8.9 mol% (14.9 wt%), a size around 40 nm, and a clear negative Z poten-
tial (Fig. 1, Table 1, and Tables S2 and S3).
To study the uptake of St-PGA-LC-BDMC by cultured tubular cells, we took advantage from the intrinsic 
fluorescence of BDMC to monitor its uptake and intracellular delivery over time. St-PGA-LC-BDMC was taken 
up by tubular cells in a time-dependent fashion from 1 h onward and with a maximum visualization at 6 h thus 
demonstrating that the conjugate may permeate the cytoplasmic membrane. In addition, the fluorescence pattern 
changed from punctuated and distributed all over the cytoplasm to aggregates with mainly perinuclear location, 
suggesting lysosomal targeting (Fig. 1B). Indeed, lysosomal delivery of St-PGA-LC-BDMC at 6 h was confirmed 
in living cells by colocalization with acidic compartments stained with the fluorescent dye Lysotracker Green 
(Supplentary Fig. S1).
St-PGA-CL-BDMC displays potent antiapoptotic effects in cultured renal tubular cells. We 
stimulated murine MCT renal tubular cells with a combination of proinflammatory cytokines (Tweak/TNFα/
INFγ, hereafter named as TTI) previously shown to induce apoptosis30, in the presence of St-PGA-CL-BDMC 
or vehicle to explore a potential role for our polymer-drug conjugate in the prevention of renal cell death. The 
MTT assay established that TTI treatment induced a ~70% loss in cell metabolic activity/viability compared to 
untreated control cells at 24 h (Fig. 2A). Encouragingly, we discovered a significant attenuation of cell metabolic 
activity/viability loss following treatment with St-PGA-CL-BDMC (54% decrease at 0.25 µM eq., reaching a pla-
teau of 31% decrease at 0.5 µM St-PGA-CL-BDMC eq.) (Fig. 2A).
In a second set of experiments using flow cytometry analysis, we discovered a significantly lower percentage 
of apoptotic hypodiploid cells induced by TTI following cotreatment with 2.5–10.0 µM St-PGA-CL-BDMC eq., 
thus confirming antiapoptotic properties of St-PGA-CL-BDMC (Fig. 2B). Moreover, LDH activity in culture 
supernatants of tubular cells stimulated with TTI was partially but significantly inhibited by St-PGA-CL-BDMC, 
meaning that the BDMC conjugate decreased TTI-induced membrane permeabilization and therefore necrosis 
(Fig. 2C). Furthermore, we explored whether St-PGA-CL-BDMC may also inhibit necroptosis, a main type of 
regulated necrosis actively involved in AKI. We have previously shown that cotreatment of renal tubular cells with 
the general caspase inhibitor z-VAD-fmk in combination with TTI (z/TTI) switches the mechanism of cell death 
from apoptosis to necroptosis30,31. In our experiments, z/TTI stimulation lowered the metabolic activity/viability 
of renal tubular cells by ~70% when compared to untreated control cells (Fig. 2D). However, results obtained 
with 10.0 µM St-PGA-CL-BDMC indicated an efficient blockade of the necroptosis pathway by preventing both, 
the z/TTI-induced loss of metabolic activity/viability and associated morphological changes (Fig. 2D,E) and the 
phosphorylation of the protein kinase MLKL, which is considered the final event triggering the necroptosis exe-
cution (Fig. 2F). We also explored the impact of St-PGA-CL-BDMC on the activation of caspase-8, a key caspase 
whose state of activation determines the occurrence of apoptosis (when active) or necrosis (when inhibited) 
(Fig. 2G). In tubular cells, TTI promoted caspase-8 cleavage, resulting in the appearance of early (45 kDa) and late 
(18 kDa) proteolytic fragments. Exposure to z/TTI, which induces necroptosis, inhibited the late activation step of 
caspase-8 almost completely but did not efficiently prevent the initial processing step resulting in the generation 
of the 45 kDa fragment. Similar to the necroptosis inhibitor necrostatin, which also inhibits TTI-induced cell 
death9, PG-BDMC prevented caspase-8 processing to 45 and 18 kDa fragments in presence of TTI or z/TTI, thus 
suggesting that it prevents cell death upstream of caspase-8 activation but contrary to zVAD, it does not trigger 
necroptosis (Fig. 2G).
Finally, we explored the protective effect of free BDMC and curcumin, chosen as the most representative and 
widely studied curcuminoid, in tubular cells stimulated with TTI. Neither free BDMC (Fig. 3A) nor curcumin 
(Fig. 3B) displayed toxicity within the same concentration range in which St-PGA-CL-BDMC protected against 
TTI-induced apoptosis (0.6–10 µM). However, in contrast with St-PGA-CL-BDMC, neither 0.6–10 µM free 
BDMC nor 2.5–10 µM curcumin offered any protection against TTI-induced cell death (Fig. 3A,B). These results 
demonstrate that conjugation enhances the antiapoptotic potency of the curcuminoid, likely through increased 
BDMC intracellular bioavailability.
St-PGA-CL-BDMC inhibits NF-κB activation and downstream gene expression of proinflam-
matory, tubular stress, and regenerative markers in renal tubular cells. NF-κB activation is a 
hallmark of the tubular cell stress response during AKI, and its prevention decreases the uncontrolled signal-
ing that amplifies inflammatory events, which in turn promotes cell death32,33. Treatment of tubular cells with 
10 µM eq. St-PGA-CL-BDMC for 30 min prevented TTI-induced NF-κB/p65 nuclear translocation (Fig. 4A) and 
MLKL protein levels (p-MLKL) in cultured MCT cells following 20 µM z-VAD-fmk plus TTI (z/TTI) or 10 µM 
St-PGA-CL-BDMC/zTTI stimulation. The figure shows a representative Western blot and the corresponding 
band quantification (n = 2 independent experiments). (G) Representative western blot of cleaved caspase-8 
in MCT cells exposed to TTI or z/TTI alone or following pretreatment with 10 µM St-PGA-CL-BDMC (n = 2 
experiments with similar results).
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decreased the expression of NF-κB-dependent genes such as those encoding the chemokines Ccl2 (MCP1) and 
Ccl5 (Rantes) (Fig. 4B), the proinflammatory Tweak receptor Fn14 (Fig. 4C), the tubular injury marker Lcn2 
(Fig. 4D), and the renal repair-associated transcription factor Sox9 (Fig. 4E).
St-PGA-CL-BDMC preserves renal function in murine nephrotoxic AKI. As St-PGA-CL-BDMC 
prevented critical processes involved in AKI pathogenesis in cultured tubular cells, we next explored the nephro-
protective potential of our novel conjugate in vivo in mice with FA-AKI. We administered St-PGA-CL-BDMC 4 h 
before FA dosage. While FA-AKI led to increased plasma urea (Fig. 5A) and creatinine levels (Fig. 5B), however, 
St-PGA-CL-BDMC treatment significantly prevented against the AKI-induced urea and creatinine raise thus 
protecting from loss in renal function (Fig. 5A,B). AKI was associated to an spectrum of histological tubulointer-
estitial lesions including extensive areas of necrotic and apoptotic cell death and of tubular cell proliferation that, 
in accordance with the better renal function, were milder in mice cotreated with St-PGA-CL-BDMC (Fig. 5C) 
(Supplementary Fig. S2).
St-PGA-CL-BDMC prevents tubular injury and maladaptive signaling in murine nephrotoxic 
AKI. Proximal tubular cell death during AKI is a critical event that results in the amplification of kidney 
injury3. In vivo evaluation of cell injury and death revealed that tubular injury, indicated by an increased number 
of TUNEL-stained (Fig. 6A) and active caspase-3 positive (Fig. 6B) tubular cells, compared to control animals, 
characterized FA-AKI. St-PGA-CL-BDMC treatment prevented the increase in TUNEL-positive (Fig. 6A,C) and 
caspase-3-positive (Fig. 6B,D) tubular cells, thus confirming that St-PGA-CL-BDMC inhibits renal tubular cell 
apoptosis in vivo.
Tubular cell death triggers adaptive mechanisms that eventually lead to recovery of renal structure and func-
tion, including tubular proliferation. Accordingly, we observed that St-CL-PGA-BDMC, in addition to reduce 
tubular apoptosis (Fig. 1A–B), also significantly decreased the resulting increase in tubular cell proliferation, as 
assessed by a lower number of PCNA positive tubular cells (Fig. 7A,B). Nuclear phosphorylation/activation of 
c-JUN is a known driver of maladaptive signaling leading to kidney fibrosis34. Compared to untreated FA-AKI 
mice, kidneys from animals treated with St-PGA-CL-BDMC exhibited lower levels of nuclear phospho-c-JUN as 
assessed by Western blot (Fig. 7C,D) (Supplementary Fig. S3) and further localized in tubular cells by immuno-
histochemistry (Fig. 7E).
Figure 3. Free BDMC and curcumin do not protect from TTI-induced cell death. Cultured MCT cells were 
exposed to TTI alone for 24 h or following pre-treatment with free BDMC (A) or curcumin (B) for 1 h before 
TTI addition. (A–B) The percentage of cell viability was assessed by the MTT assay. Curcuminoids were not 
toxic by themselves but did not prevent TTI-associated toxicity. Bar charts represent the mean ± SD of 3–5 
individual experiments. #p < 0.001 vs control.
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Overall, the reduction in tubular cell injury and death and preserved renal function in association with 
lower tubular proliferation and the recruitment of signaling pathways involved in both repair and maladaptive 
responses suggests that St-PGA-CL-BDMC treatment prevents both AKI and the subsequent tissue responses that 
eventually lead to chronic injury.
We next focused on the impact of St-PGA-CL-BDMC on mediators of tubular cell death and inflammation.
St-PGA-CL-BDMC inhibits ferroptosis and reduces related oxidative stress markers in 
FA-AKI. We recently demonstrated that ferroptosis, a regulated necrosis program, is an essential driver of the 
initial wave (24–48 h) of tubular cell death in FA-AKI6. In association with the above cell death increase at 48 h 
(Fig. 6), analysis of kidneys from FA-AKI mice revealed the development of critical features of ferroptosis, such 
as increased lipid peroxidation as assessed by increased 4-hydroxynonenal (4-HNE) staining by immunohisto-
chemistry (Fig. 8A) and IL-33 proteolytic processing to its proinflammatory form as evaluated by Western blot 
(Fig. 8B) (Supplementary Fig. S4). Interestingly, St-PGA-CL-BDMC also diminished 4-HNE formation (Fig. 8A) 
and the proinflammatory fragmentation of IL-33 (Fig. 8B,C) (Supplementary Fig. S4).
Lipid peroxidation leading to cell membrane disruption and ferroptosis is a consequence of oxidative stress 
and reactive oxygen species (ROS) formation. In this regard, FA-AKI kidneys displayed increased mRNA and 
protein levels of the oxidative stress markers heme oxigenase 1 (HO-1) (Fig. 8B,D) (Supplementary Fig. S4) and 
NAD(P)H dehydrogenase (quinine 1) (NQO-1) (Fig. 8E), which was prevented by St-PGA-CL-BDMC treatment 
(Fig. 8B,D,E) in agreement with the observation of lower 4-HNE staining in these animals.
Figure 4. St-PGA-CL-BDMC inhibits TTI-induced NF-κB activation and proinflammatory activity in cultured 
renal tubular cells. (A) MCT cells were stimulated with TTI alone for 30 min or following pretreatment for 
1 h with 10 µM St-PGA-CL-BDMC. NF-κB nuclear translocation/activation was assessed by fluorescence 
immunocytochemistry and confocal microscopy of the RelA/p65 subunit. The figure is a representative 
experiment showing that TTI induces the nuclear translocation of p65 (green fluorescence) and this is 
inhibited by St-PGA-CL-BDMC. Nuclei were counterstained with DAPI (blue fluorescence). The experiment 
was replicated for at least three times. Original magnification x 200. (B–E) Relative mRNA expression of NF-
κB-dependent genes CCL5 and CCL2 (#p < 0.001 vs control; *p < 0.05 vs TTI; **p < 0.01 vs TTI) (B), Fn14 
(#p < 0.001 vs control; *p < 0.05 vs TTI) (C); LCNA (#p < 0.001 vs control; *p < 0.05 vs TTI) (D) and SOX9 
(#p < 0.001 vs control; *p < 0.05 vs TTI) (E) assessed by q-RT-PCR in MCT cells stimulated for 6 h with TTI 
alone or following pre-treatment with 2.5–25 µM (B) or 10 µM St-PGA-CL-BDMC (C–E). Results are presented 
as mean ± SD of at list 3 experiments.
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Overall, our data suggest that St-PGA-CL-BDMC may also protect from ferroptosis thus contributing to 
nephroprotection in FA-AKI.
St-PGA-CL-BDMC downregulates NF-κB pathway activation in FA-AKI. Since cell culture stud-
ies demonstrated that St-PGA-CL-BDMC prevented NF-κB/p65 nuclear translocation and the subsequent 
transcription of NF-κB target genes involved in the pathogenesis of AKI (Fig. 4), we explored the impact of 
St-PGA-CL-BDMC in kidneys from mice with FA-AKI in this regard. Increased renal levels and activation 
of NF-κB in FA-AKI mice was apparent from higher cytoplasmic as well as nuclear p65 levels, respectively 
(Fig. 9A,B) (Supplementary Fig. S5), increased Lcn2 (Fig. 9C) and Fn14 (Fig. 9D) mRNA levels, and decreased 
mRNA expression of the negatively regulated NF-κB target, Klotho (Fig. 9E). Remarkably, St-PGA-CL-BDMC 
prevented these responses (Fig.  9A–E), suggesting that inhibition of NF-κB activation has a role in 
St-PGA-CL-BDMC-induced nephroprotection.
Discussion
The lack of effective AKI treatments currently contributes to acute mortality from AKI and chronic compli-
cations, such as progression to CKD, and its own associated high mortality risk35–37 2498855838. We have 
synthesized a novel polymer-drug conjugate, St-PGA-CL-BDMC, that provides the beneficial activities of cur-
cuminoids with an improved pharmacokinetic profile afforded by polymer conjugates, and we also characterized 
Figure 5. In vivo treatment with St-PGA-CL-BDMC prevents renal dysfunction and injury provoked by FA-
induced AKI. C57/BL6 mice were injected with vehicle (Cont, n = 7), folic acid (FA-AKI, n = 10), or St-PGA-
CL-BDMC and folic acid (FA-AKI + St-PGA-CL-BDMC, n = 10). St-PGA-CL-BDMC significantly decreased 
the severity of renal dysfunction by lowering the plasma levels of urea (A) and creatinine (B) induced by AKI. 
Bar graphs represent the mean ± SD of the entire set of animals in each group for both urea (#p < 0.01 vs control; 
*p < 0.01 vs FA-AKI) and creatinine (#p < 0.001 vs control; *p < 0.001 vs FA-AKI). (C) St-PGA-CL-BDMC 
prevents histological evidence of AKI. Kidney tissue sections were stained with H&E (left panel) and the tissue 
integrity assessed by an injury score (right panel). Representative microphotographs showing typical injury 
signs in AKI that were decreased by St-PGA-CL-BDMC: apoptotic cells (black arrow), tubular necrosis (cell 
detachment, intratubular cell debris) (red arrows), mitotic cells (black arrowhead), nuclei size and chromatin 
compactation heterogeneity (yellow arrows). #p < 0.01 vs control; *p < 0.05 vs FA-AKI. Original magnification 
400x. Scale bar 25 µm.
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its nephroprotective potential in AKI. Furthermore, we identified critical targets of the nephroprotective effect, 
including NF-κB activation and interference with apoptosis and regulated necrosis pathways.
Curcuminoids are widely used medications in Indian ayurvedic and traditional oriental medicine. Recently, 
numerous studies have explored their mechanisms of action11,39, with curcuminoids discovered to display 
anti-inflammatory, antiproliferative, and antioxidative properties that may be harnessed to treat acute and 
chronic human disease. However, curcuminoids exhibit certain disadvantages, including low bioavailability and 
Figure 6. In vivo treatment with ST-PGA-CL-BDMC reduces cell death and caspase-3 activation in FA-AKI. 
Renal cell death was assessed by TUNEL staining (A,C) or by active caspase-3 immunohistochemistry (B,D) 
in vehicle-injected mice (Control, n = 7), in mice with FA-AKI (FA-AKI, n = 10) or in mice with FA-AKI 
cotreated with St-PGA-CL-BDMC (FA-AKI + ST-PGA-CL-BDMC, n = 10). (A) St-PGA-CL-BDMC reduces 
the number of TUNEL positive cells in FA-AKI kidneys. A shows representative images corresponding to renal 
sections from Control, FA-AKI, and FA-AKI + St-PGA-CL-BDMC groups. TUNEL positive nuclei are indicated 
by arrowheads, while the arrows point areas showed at a higher magnification as detail (inserted images). 
Original magnification x 200. Scale bar 100 μm. (C) shows TUNEL quantification by counting the number of 
positive nuclei per low power field (lpf). #p < 0.001 vs control; *p < 0.05 vs FA-AKI. (B,D) St-PGA-CL-BDMC 
reduces caspase-3 activation in FA-induced AKI kidneys. B shows representative images. Asterisks identify 
representative tubules with positive staining for the processed active form of caspase-3. Original magnification 
x200. Scale bar 100 μm. The bar chart in D depicts the ratio of the active caspase-3 stained area to total area 
expressed as a percentage. #p < 0.05 vs control; *p < 0.01 vs FA-AKI. Results are presented as mean ± SD.
1 1Scientific RepoRtS |         (2020) 10:2056  | https://doi.org/10.1038/s41598-020-58974-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
suboptimal pharmacokinetic properties15,40. Nanoscale has been proven to be an appropriate strategy to overcome 
bioavailability limitations and improve the bioactivity of diet-derived phytochemicals and curcumin16,17,41,42. 
Specifically, the use of polymer therapeutics, and the development of polymer-drug conjugates, in particular, 
provide longer drug half-lives, improve pharmacokinetic/pharmacodynamic properties, and increase drug 
accumulation within inflamed/diseased/damaged tissues thanks to the enhanced retention and permeability 
effect18,43. The use of biodegradable polyglutamates as a carrier for AKI therapeutics takes advantage of their nat-
ural and significant kidney tropism23,24. Macromolecular complexes of polyglutamates, including St-PGA-based 
nanocarriers and, by extension, the therapeutic polymer assayed in the present work, typically enter cells by an 
energy-dependent endocytic process23,24,44. St-PGA-CL-BDMC is a pH-responsive functional polymer conjugate 
that allows drug delivery in acidic environments, such as inflamed tissues, e.g. areas of damaged kidney in AKI, 
or may take the endocytic-lysosomal pathway in native tubular cells also leading to a pH-aided polymer cleavage 
and drug release44,45. The large conjugate size (30–100 nm) does not support glomerular filtration as mechanism 
of urinary excretion of the unprocessed molecule. Moreover, published detailed pharmacokinetic studies showed 
plasma clearance of 1.193 ml/h and in vivo distribution of St-PGA in healthy mice characterized by efficient renal 
uptake and a wide organ distribution, including accumulation in immune cells of lymphoid organs28,29, which 
could be potentially important to control deregulated proinflammatory activity during AKI. Kidney St-PGA 
accumulation was already detected at 30 min, peaked at 8 h and remained significantly retained after 72h29, which 
Figure 7. St-PGA-CL-BDMC attenuates reparative and AKI-to-CKD transition mechanisms in FA-AKI. 
Evaluation of the impact of St-PGA-CL-BDMC treatment on key events governing regeneration or AKI-to-
CKD transition in C57/BL6 mice with FA-AKI. Mice were distributed into the following groups: vehicle-treated 
(control, n = 4–7), FA-AKI (FA-AKI, n = 7–10) and FA-AKI treated with St-PGA-CL-BDMC (FA-AKI + St-
PGA-CL-BDMC, n = 7–10). (A,B) The proliferation rate estimated by PCNA staining was lower in kidneys 
from AKI mice treated with St-PGA-CL-BDMC. Representative images of PCNA immunohistochemistry  
(A) and the corresponding quantification in the complete set of animals (B). Arrows in A show PCNA positive 
nuclear staining. Original magnification x200. Scale bar 100 μm. #p < 0.001 vs control; *p < 0.05 vs FA-AKI.  
(C) Maladaptive signaling was evaluated by the nuclear levels of phosphorylated cJUN (p-cJUN). Representative 
western blot the corresponding quantification (D) show that compared to control kidneys, the nuclear content 
of p-cJUN increased in kidneys from FA-AKI mice and St-PGA-CL-BDMC significantly prevented this effect. 
Specific bands were matched against Ponceau red stained bands used as loading control. #p < 0.001 vs control; 
*p < 0.05 vs FA-AKI. (E) Renal p-cJUN was localized by immunohistochemistry. Images from representative 
animals for each experimental group showing higher nuclear p-cJUN content in FA-AKI than in control mice or 
St-PGA-CL-BDMC-treated AKI mice. Asterisks indicate tubules with high p-cJUN expression and arrows point 
individual positive nuclei. Original magnification x 400. Scale bar 100 μm Results are presented as mean ± SD.
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could account for the in vivo St-PGA-CL-BDMC inhibitory effects during AKI. The long half-life of the retained 
fraction of St-PGA-CL-BD in kidney is consistent with catabolism within tubular cells. St-PGA-CL-BDMC 
displayed an improved pharmacokinetic profile when compared to unconjugated curcuminoids, as evidenced 
by the in vitro and in vivo results obtained herein. In vitro, in cultured renal tubular cells, St-PGA-CL-BDMC 
afforded significant protection from cytotoxicity at concentrations 100-fold lower than the unconjugated “free” 
form of BDMC and in vivo, St-PGA-CL-BDMC prevented AKI at doses 25–50 times lower than those commonly 
employed in experimental AKI treatment with curcuminoids, which are between 100–200 mg/kg/day when 
administered orally or through the peritoneal parenteral route46,47. These results agree with our previous findings 
showing the suitability of St-PGA for lysosomotropic drug delivery in tumour cells23,24 and now add renal epi-
thelial cells as St-PGA-LC-BDMC targets. As renal tubular cell death is the pivotal pathological event involved 
in the initiation and propagation of renal damage during AKI3, we reasoned that targeting tubular cell death and 
proinflammatory activity by St-PGA-CL-BDMC may contribute to prevent AKI. Moreover, as cell uptake studies 
strongly suggested that lysosomotropism may be a general mechanism of St-PGA-CL-BDMC cell uptake, it may 
be speculated that conjugate uptake by other cell types involved in AKI (e.g endothelium cells or leukocytes) may 
also contribute to nephroprotection.
Moreover, protection from AKI validates the retro-orbital route for a timely St-PGA-CL-BDMC delivery, thus 
offering simplicity in the conjugate administration and an easy access of the same to the blood stream. This data 
suggests a rapid absorption of the conjugate into the bloodstream as a consequence of its high solubility in aque-
ous medium, which mainly differs from the insoluble nature of free curcuminoids in polar aqueous solvents that 
preclude the retro-orbital administration of free BDMC for comparative purposes.
Figure 8. St-PGA-CL-BDMC treatment prevents key renal cell death and oxidative stress pathways in FA-AKI. 
Groups of animals were the same as in preceding figures. (A) Representative IHC images of 4-Hydroxynonenal 
(4-HNE) staining in mice with AKI and the corresponding quantification including all mice in each experimental 
group. St-PGA-CL-BDMC decreased FA-AKI-induced 4-HNE staining. #p < 0.001 vs control; *p < 0.05 vs FA-
AKI. Original magnification x200. Scale bar 100 μm. (B) Representative western blot detection of cleaved IL-33 
and heme oxygenase-1 (HO-1) in total kidney protein extracts from control, AKI or AKI/St-PGA-CL-BDMC 
mice. St-PGA-CL-BDMC prevented kidney IL-33 processing/activation and upregulation of HO-1 expression. 
(C,D) Quantification of IL-33, #p < 0.001 vs control; *p < 0.05 vs FA-AKI (C) and HO-1, #p < 0.05 vs control; 
*p < 0.05 vs FA-AKI. (D) western blots including the complete set of animals. (E) Nqo-1 mRNA expression 
assessed by q-RT-PCR in kidneys from control mice and in mice with FA-AKI left untreated or treated with ST-
PGA-CL-BDMC. #p < 0.001 vs control; *p < 0.05 vs FA-AKI. Results are presented as mean ± SD.
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Our studies confirmed previously published mechanisms of action of curcuminoids in tissue protection, 
such as the prevention of NF-κB activation and high antioxidant activities, but also provided novel findings 
regarding the interference of molecular pathways involved in regulated necrosis. In cultured renal tubular cells, 
St-PGA-CL-BDMC protected from apoptosis, a primary driver of AKI initiation and amplification46,48. This 
result agrees with the reported antiapoptotic activity of curcuminoids in renal cells, and also demonstrated that 
St-PGA-CL-BDMC, but not the free forms of BDMC or curcumin, inhibited apoptosis at low equimolar doses, 
suggesting the enhanced bioavailability when formulated as a polymer-drug conjugate. In this regard, unlike free 
curcuminoids that enter the cells by passive diffusion, polymer-conjugates require an energy-dependent mech-
anism for cellular uptake18. After endocytosis, the conjugated drug then accumulates in the lysosome thereby 
avoiding detoxifying mechanisms such as ATP-binding cassette and efflux pumps. Following polymer and/
or linker degradation, the drug is then released to the cytosol45. Of note, lysosomal cathepsins are involved in 
lysosome-mediated apoptosis in several pathological processes including renal diseases and AKI, and, as recently 
reported, in ferroptosis49,50. Moreover, previous studies have revealed that curcumin restrains the leakage of 
hydrolases by an effect that depends on the lysosomal membrane stabilization51. This findings suggest that in 
our system, following to both lysosomotropic delivery of St-PGA-CL-BDMC and its own hydrolityc cleavage, 
free BDMC also contribute to inhibit the apoptosis promoted by lysosomal enzymes by restoring the lysosomal 
membrane functionality. In agreement with the in vitro results, St-PGA-CL-BDMC also decreased in vivo cell 
death (lower numbers of renal TUNEL positive cells) and tubular caspase-3 activation in FA-AKI. However, 
TUNEL may also detect caspase-independent cell death, such as forms of regulated necrosis-like necroptosis and 
ferroptosis implicated in AKI pathogenesis6,9,52. Studies have established that curcumin protects hepatocytes and 
neurons from necroptosis, although kidney cells have not been studied53,54. Our results in cultured renal tubular 
cells demonstrated that St-PGA-CL-BDMC-mediated inhibition of z-VAD/TTI-induced necroptosis, as assessed 
by the inhibition of cell death and MLKL phosphorylation, add a new perspective in the explanation of the lower 
severity of cell death observed in AKI mice treated with the St-PGA-CL-BDMC. Unfortunately, difficulties for 
detection of phosphorylated MLKL in mouse kidney6,9 precluded verifying a direct effect of St-PGA-CL-BDMC 
on AKI-induced necroptosis in vivo. Also, St-PGA-CL-BDMC decreased the expression of ferroptosis markers 
in kidneys from FA-AKI, identifying a previously uncharacterized modulation by curcuminoids of this regulated 
necrosis cell death mechanism. Recent investigations of our laboratory established that ferroptosis is a crucial 
mechanism initiating AKI, whereas necroptosis mediates a second, amplificatory wave of cell death6,9.
Curcuminoids inhibit activation of NF-κB, a critical proinflammatory transcription factor in kidney disease32. 
St-PGA-CL-BDMC treatment downregulated NF-κB activation and downstream events in cultured renal tubu-
lar cells, including expression of genes associated with inflammation (CCL2, CCL5/Fn14) and tubular damage 
Figure 9. St-PGA-CL-BDMC downregulates NF-κB activation in FA-AKI. (A) Representative western blot of 
p65 assessed in kidney nuclear (p65 (N)) and cytoplasmic (p65 (C)) extracts showing that St-PGA-CL-BDMC 
prevented the FA-AKI-induced increase in NF-κB levels and nuclear translocation. Protein associated-fluorescence 
was used as loading control and a representative fluorescent band showed as inverted image. (B) Quantification 
of nuclear p65 (p65(N)) assessed by western blot in the complete set of mice. #p < 0.05 vs control; *p < 0.05 vs 
FA-AKI. (C–D) The Lcn2 and Fn14 relative renal mRNA expression is significantly lower in St-PGA-CL-BDMC-
treated FA-AKI mice. #p < 0.001 vs control; *p < 0.05 vs FA-AKI. (E) St-PGA-CL-BDMC treatment prevents the 
FA-AKI-induced reduction in kidney Klotho mRNA levels. #p < 0.001 vs control; *p < 0.05 vs FA-AKI.
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(Lcn2). Moreover, St-PGA-CL-BDMC treatment also inhibited these and other NF-κB-dependent responses in 
FA-AKI mice concomitant to repression of NF-κB/p65 upregulation and nuclear translocation. Whereas lower 
levels of HO-1, Lcn2 and PCNA in a context of preserved function may reflect the milder renal injury55, the 
inhibition of FA-AKI-induced Fn14 expression and Klotho suppression could also contribute to the downreg-
ulation of AKI-associated inflammation, thus preventing the amplification of injury. In this regard, Fn14 tar-
geting decreases the severity of FA-AKI and limits kidney inflammation and necroptosis9, while Klotho has 
anti-inflammatory, tissue-protective, and anti-fibrotic properties56.
In conclusion, we present St-PGA-CL-BDMC as a novel polymer-drug conjugate that displays the potent 
nephroprotective properties common to other curcuminoids, but with a more favorable pharmacokinetic profile. 
St-PGA-CL-BDMC protected cultured renal tubular cells at lower concentrations that non-conjugated free cur-
cuminoids and protected from AKI through the inhibition of NF-κB activation and interference with molecular 
pathways driving cell death through apoptosis and the necroptosis and ferroptosis forms of regulated necrosis. 
These properties make St-PGA-CL-BDMC a candidate for future clinical studies of AKI prevention and therapy.
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